Design Cloud

  • Home

  • About Us

    Company Profile HIstory Culture Honor
    • Company Profile

    • HIstory

    • Culture

    • Honor

  • Products

    Cardiovascular series Psychiatry series Hepatobiliary, Gastroenterology Series Respiratory series Anti-infective virus series Other series Large Infusion Series Huabao Tong Series Active Pharmaceutical Ingredient Series
    • Cardiovascular series

    • Psychiatry series

    • Hepatobiliary, Gastroenterology Series

    • Respiratory series

    • Anti-infective virus series

    • Other series

    • Large Infusion Series

    • Huabao Tong Series

    • Active Pharmaceutical Ingredient Series

  • R&D

    Academician Expert Workstation Medical Research and Industry Alliance
    • Academician Expert Workstation

    • Medical Research and Industry Alliance

  • News

    General News Party group dynamics Employee activity
    • General News

    • Party group dynamics

    • Employee activity

  • HR

    Talent Strategy Company recruitment
    • Talent Strategy

    • Company recruitment

  • Contact us

  • 中文版

Image Name

News

  • Home page

General News

Party group dynamics

Employee activity

Wanbangde Pharmaceutical Group Co., Ltd. Announces Public Disclosure of the Environmental Impact Assessment for a New Project Producing 609 kg of Phloroglucinol Dihydrate Intermediate Annually

Date:

01 Mar,2021


The full text is attached. Click to download

Previous page

An invention patent has been authorized by the National Intellectual Property Administration.

The unique advantages of Shuguang Holy Land's Ginkgo Leaf Droplets spark lively discussions among experts and scholars.

Next page

Related Recommendations

Image Name

2023/06/02

News | Inspection teams from the National Institute for Food and Drug Control, Zhejiang Provincial Institute of Drug Control, and Taizhou Municipal Institute of Drug Control visit Wanbangde for research and guidance

Image Name

2023/06/02

"Building Momentum Gradually | Postdoctoral Research Workstation Accelerates Ahead, Bolstering Pharmaceutical Group’s Scientific Innovation with Fresh Talent!"

Image Name

2023/06/02

Brand Revitalization | The 2023 China Brand Value Evaluation Report Released—Wanbangde Pharmaceutical Group Listed Again!

< 1...272829...78 > proceed page
  • Home

  • About Us

    • Company Profile

    • HIstory

    • Culture

    • Honor

  • Products

    • Cardiovascular series

    • Psychiatry series

    • Hepatobiliary, Gastroenterology Series

    • Respiratory series

    • Anti-infective virus series

    • Other series

    • Large Infusion Series

    • Huabao Tong Series

    • Active Pharmaceutical Ingredient Series

  • R&D

    • Academician Expert Workstation

    • Medical Research and Industry Alliance

  • News

    • General News

    • Party group dynamics

    • Employee activity

  • HR

    • Talent Strategy

    • Company recruitment

  • Contact us

  • 中文版

Image Name

Website Development: China Enterprise DynamicsTaizhou

Business license
浙ICP备10002622号-38